Tumor lysis syndrome: Difference between revisions

(spelling error)
(format and ref added)
Line 14: Line 14:
#Tumor infiltration of the kidney
#Tumor infiltration of the kidney


===Cairo-Bishop Definition===
===Cairo-Bishop Definition<ref>Cairo MS and Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol. 2004; 127(1):3–11.</ref>===
*Laboratory Tumor Lysis Syndrome
'''Laboratory Tumor Lysis Syndrome'''
**Abnormality in 2 or more of the following, occurring w/in 3d before or 7d after chemo:
*Abnormality in 2 or more of the following, occurring w/in 3d before or 7d after chemo:
#Uric acid ≥ 8 mg/dL or 25% increase from baseline
**Uric acid ≥ 8 mg/dL or 25% increase from baseline
#Potassium ≥ 6mEq/L or 25% increase from baseline
**Potassium ≥ 6mEq/L or 25% increase from baseline
#Phosphate ≥ 4.5 mg/dL or 25% increase from baseline (≥ 6.5 for children)
**Phosphate ≥ 4.5 mg/dL or 25% increase from baseline (≥ 6.5 for children)
#Calcium ≤ 7 mg/dL or 25% decrease from baseline
**Calcium ≤ 7 mg/dL or 25% decrease from baseline
*Clinical Tumor Lysis Syndrome
'''Clinical Tumor Lysis Syndrome'''
**Laboratory tumor lysis syndrome plus 1 or more of the following:
*Laboratory tumor lysis syndrome plus 1 or more of the following:
#Cr > 1.5 times upper limit of age-adjusted reference range
**Cr > 1.5 times upper limit of age-adjusted reference range
#Cardiac dysrhythmia or sudden death
**Cardiac dysrhythmia or sudden death
#Seizure
**Seizure


==Clinical Features==
==Clinical Features==

Revision as of 02:49, 3 March 2015

Background

  • Associated w/ treatment of ALL, Burkitt lymphoma, NHL
    • Rarely observed in solid tumors or without prior therapy
  • Rapid turnover of tumor cells (spontaneously or after Rx) leading to release of:
    • Potassium
    • Phosphate
    • Uric acid (converted from nucleic acids)

Risk Factors

  1. High cell proliferation rate
  2. Large tumor burden (LDH) > 1500 IU/L, WBC ≥ 50 x 103 cells/L
  3. Extensive BM involvement
  4. Tumor infiltration of the kidney

Cairo-Bishop Definition[1]

Laboratory Tumor Lysis Syndrome

  • Abnormality in 2 or more of the following, occurring w/in 3d before or 7d after chemo:
    • Uric acid ≥ 8 mg/dL or 25% increase from baseline
    • Potassium ≥ 6mEq/L or 25% increase from baseline
    • Phosphate ≥ 4.5 mg/dL or 25% increase from baseline (≥ 6.5 for children)
    • Calcium ≤ 7 mg/dL or 25% decrease from baseline

Clinical Tumor Lysis Syndrome

  • Laboratory tumor lysis syndrome plus 1 or more of the following:
    • Cr > 1.5 times upper limit of age-adjusted reference range
    • Cardiac dysrhythmia or sudden death
    • Seizure

Clinical Features

  1. Hyperuricemia
    1. N/V, lethargy, renal failure
  2. Hyperkalemia
    1. Most immediate life-threatening element (due to dysrrhythmias)
  3. Hyperphosphatemia
    1. May combine w/ Ca to precipiate in renal tubules
  4. Hypocalcemia
    1. Anorexia, cramping, tetany, confusion, seizures, V-tach/torsades
  5. Acute Renal Failure
    1. Most common cause of morbidity
    2. Usually results from uric acid precipitation within renal tubules

Work Up

  1. CBC
  2. Chemistry
  3. Calcium, phosphate
  4. Uric Acid
  5. LDH
  6. UA
  7. ECG
    1. HyperK, hypoCa

Imaging

  • Avoid IV contrast

Treatment

  1. Agressive hydration
    1. Goal urine output is 3L in 24hr

Hypocalcemia

  • ≤7 or 25% dec in baseline
    • Treat only if symptomatic (increased Ca leads to increased Ca/phos deposition), such as widened QRS or ventricular arrhythmias
    • Calcium gluconate 50-200mg IV

Hyperphosphatemia

  • ≥4.5 or 25% increase; ≥ 6.5mg/dL in children
    • IV insulin & glucose
    • Phosphate Binder - Aluminum hydroxide (50-150mg/kg PO q4-6h) - limited effect
    • Dialysis if refractory

Hyperuricemia

  • ≥8 or 25% increase
    • Allopurinol
      • Acts slowly; only helpful for preventing future production of uric acid
      • 10mg/kg/d PO q8 OR 200-400 mg/m2 IV q12; renally dosed
      • Inhibition of xanthine oxidase can last 18-30h
    • Urate Oxidase Rx
      • Rasburicase 0.05-0.2mg/kg IV)
      • Can be used for BOTH prevention and treatment
      • Uric acid final product of purine metabolism
        • Urate oxidase converts uric acid to allantoin (5-10x more soluble)

Hyperkalemia

  • Only give Ca for cardiovascular instability (e.g.ventricular arrhythmias, widened QRS)
    • Giving Ca leads to increased Ca/phos deposition which leads to renal failure
  • See Hyperkalemia for treatment options

Dialysis (Criteria)

  1. K >6
  2. Significant renal insufficiency (Cr >10)
  3. Uric Acid >10
  4. Symptomatic hypocalcemia
  5. Serum phosphorus >10
  6. Volume overload

Disposition

  • Admit (often to ICU)

Source

  • Tintinalli
  • EM Practice March '10
  1. ↑ Cairo MS and Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol. 2004; 127(1):3–11.
Retrieved from "https://www.wikem.org/w/index.php?title=Tumor_lysis_syndrome&oldid=33143"